Trials / Completed
CompletedNCT02048176
Posterior Fossa Mutism on Quality of Life
Long-Term Impact of Posterior Fossa Mutism on Quality of Life
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (actual)
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago · Academic / Other
- Sex
- All
- Age
- 8 Years – 25 Years
- Healthy volunteers
- Not accepted
Summary
Posterior fossa mutism (PFM) occurs in up to 30% of patients after resection of a posterior fossa tumor, most commonly a medulloblastoma. PFM is characterized by delayed onset of mutism 1-6 days after surgery that can spontaneously improve on average from 7-8 weeks later. Few patients recover normal speech. Most of their speech continues to be marked by dysarthria, dysfluency and slowed rate. Researchers have not identified the pathophysiologic mechanism for PFM nor have they found a cure. Despite the improvements in speech, patients with PFM have shown multiple areas of neurocognitive deficits 12 months after diagnosis. Few studies have looked at long term outcomes of patients affected by PFM. We propose to survey patients who developed PFM after resection of a medulloblastoma to determine long term effects of PFM on patient's quality of life.
Conditions
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2014-01-29
- Last updated
- 2024-08-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02048176. Inclusion in this directory is not an endorsement.